Enhertu breast cancer drug now available on NHS in England
Incurable breast cancer patients in England can now access the life-extending drug Enhertu following NICE's updated cost-effectiveness thresholds.
Stock photo for illustration only, not from the actual event
- HER2-low breast cancer patients in England can now access Enhertu via NHS.
- The drug extends life expectancy by an average of nearly seven months.
- NICE reversed its prior decision after raising the QALY upper threshold to £35,000.
- The policy shift is expected to impact approximately 1,000 women annually.
Patients in England suffering from specific types of incurable breast cancer have received a major breakthrough as the life-extending medication Enhertu has officially been included in the National Health Service (NHS) offerings. This milestone arrives two years after health authorities previously deemed the treatment too expensive.
Clinical data indicates that Enhertu can grant patients nearly seven additional months of life on average, with certain individuals living up to three years longer. Women residing in Scotland have already enjoyed access to the treatment through the NHS since 2023, while availability spans across 26 other European nations, and Wales is anticipated to follow suit shortly.
Stock photo for illustration only, not from the actual event
The policy reversal follows relentless campaigning by patient advocacy groups and charities since 2024, after the National Institute for Health and Care Excellence (NICE) initially ruled that Enhertu offered poor value for money. Doctors throughout England are now authorized to prescribe the medication starting Thursday, although the guidance does not automatically extend to Northern Ireland.
"Enhertu can be life-changing, and this recommendation means NHS patients will finally be able to benefit from it."
Health Secretary Yvette Cooper emphasized that Enhertu possesses life-changing potential, noting that the recommendation allows NHS patients to finally reap its benefits while praising the tireless perseverance of campaigners and charities.
NICE's decision underscores the shifting paradigms in health economic evaluations. The Quality-Adjusted Life Year (QALY) framework serves as a critical benchmark for determining whether public pharmaceutical investments yield sufficient clinical value. Elevating the cost-per-QALY threshold from £30,000 to £35,000, combined with modernized quality-of-life measurement methods introduced in late August, illustrates how governmental trade policies and intense public lobbying can successfully reshape healthcare reimbursement frameworks for high-cost oncology therapies.
The approval will directly impact roughly 1,000 women annually diagnosed with HER2-low metastatic breast cancer, a form of the disease that has spread to areas such as bones and lungs. Among them is 51-year-old Kate Wills, who manages her terminal diagnosis while maintaining an active career and family life, driven by her goal to live long enough to see her children finish school.
Reports indicate that pharmaceutical manufacturers Daiichi Sankyo and AstraZeneca did not substantially reduce their original pricing. Instead, NICE altered its stance primarily due to a broader trade agreement with the United States requiring the UK government to increase medical spending by 25%, alongside the upward revision of the QALY threshold and the implementation of more nuanced quality-of-life assessment metrics.
Source: BBC Health
Found something wrong in this article? Report an issue with this article
Comments
Leave a Comment